These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21204763)

  • 21. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
    Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
    J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
    Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proof of Therapeutic Efficacy of a
    Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
    J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
    J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
    Sundberg AL; Gedda L; Orlova A; Bruskin A; Blomquist E; Carlsson J; Tolmachev V
    Cancer Biother Radiopharm; 2004 Apr; 19(2):195-204. PubMed ID: 15186600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of
    Galbiati A; Bocci M; Ravazza D; Mock J; Gilardoni E; Neri D; Cazzamalli S
    J Nucl Med; 2024 Oct; 65(10):1604-1610. PubMed ID: 39266289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
    Yook S; Lu Y; Jeong JJ; Cai Z; Tong L; Alwarda R; Pignol JP; Winnik MA; Reilly RM
    Biomacromolecules; 2016 Apr; 17(4):1292-302. PubMed ID: 26974228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice.
    Vilchis-Juárez A; Ferro-Flores G; Santos-Cuevas C; Morales-Avila E; Ocampo-García B; Díaz-Nieto L; Luna-Gutiérrez M; Jiménez-Mancilla N; Pedraza-López M; Gómez-Oliván L
    J Biomed Nanotechnol; 2014 Mar; 10(3):393-404. PubMed ID: 24730235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
    Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
    J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.
    Harris TD; Cheesman E; Harris AR; Sachleben R; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Silva P; Robinson S; Lazewatsky J; Rajopadhye M; Barrett J
    Bioconjug Chem; 2007; 18(4):1266-79. PubMed ID: 17579472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer.
    Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S
    Nucl Med Biol; 2008 Jul; 35(5):589-97. PubMed ID: 18589303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.
    Bozon-Petitprin A; Bacot S; Gauchez AS; Ahmadi M; Bourre JC; Marti-Batlle D; Perret P; Broisat A; Riou LM; Claron M; Boturyn D; Fagret D; Ghezzi C; Vuillez JP
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):252-63. PubMed ID: 25164771
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Pirooznia N; Abdi K; Beiki D; Emami F; Arab SS; Sabzevari O; Soltani-Gooshkhaneh S
    Bioorg Chem; 2020 Sep; 102():104100. PubMed ID: 32711088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo and in vitro evaluation of
    Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
    Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.